SEC Form 4 · accession 0000907654-26-000088
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Lee Sandler
Officer — Chief Operating Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 1, 2026 · 6:36 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | M | 5,000 | $7.80 | A | 241,384 | D | |
| Common StockF2 | Sep 1, 2026 | S | 1,000 | $91.0476 | D | 240,384 | D | |
| Common StockF3 | Sep 1, 2026 | S | 4,000 | $92.0134 | D | 236,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Warrant (right to buy)F4 | $7.80 | Sep 1, 2026 | M | 5,000 | D | — | Jul 14, 2034 | Common Stock | 5,000 | 74,996 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.51 to $91.49, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.60 to $92.59, inclusive.
- F4The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.